Welcome to our dedicated page for Atrium Therapeutics news (Ticker: RNA), a resource for investors and traders seeking the latest updates and insights on Atrium Therapeutics stock.
Avidity Biosciences, Inc. (Nasdaq: RNA) generates news flow centered on its development of Antibody Oligonucleotide Conjugates (AOCs™), a class of RNA therapeutics designed to combine monoclonal antibody specificity with oligonucleotide precision. Company announcements frequently highlight progress across its late-stage neuromuscular pipeline, including programs for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD).
News items for RNA often cover clinical trial milestones, such as topline and long-term data from the EXPLORE44® and EXPLORE44-OLE™ studies of delpacibart zotadirsen (del-zota) in DMD44, enrollment and data plans for the HARBOR™ Phase 3 trial of del-desiran in DM1, and development updates for del-brax and the FORTITUDE™ and FORTITUDE-3™ programs in FSHD. Regulatory developments are another key theme, including the FDA’s Breakthrough Therapy designation for del-zota and disclosures about planned Biologics License Application (BLA) submissions.
Investors following Avidity’s news can also expect coverage of financing activities, such as public offerings of common stock, collaboration milestones with partners like Eli Lilly and Company and Bristol Myers Squibb, and updates on the company’s cash position as reported in periodic financial results. Corporate and strategic news includes participation in scientific and investor conferences, as well as detailed announcements about the definitive merger agreement with Novartis AG and the planned separation of early-stage precision cardiology programs into a new company referred to as SpinCo.
In addition, Avidity regularly reports on its engagement with patient and advocacy communities, particularly during National Muscular Dystrophy Awareness Month and events focused on Duchenne muscular dystrophy, myotonic dystrophy, FSHD and rare diseases. For readers tracking RNA, this news page provides a centralized view of clinical, regulatory, financial and transaction-related developments that shape the company’s trajectory.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Avidity Biosciences (Nasdaq: RNA) has received FDA Fast Track designation for its RNA therapeutic, AOC 1044, intended for treating Duchenne muscular dystrophy (DMD) mutations amenable to exon 44 skipping (DMD44). This designation promotes expedited development and review processes due to the serious nature of DMD, which lacks approved therapies targeting exon 44. AOC 1044 is currently in a Phase 1/2 clinical trial, EXPLORE44™, which aims to evaluate its safety and efficacy. The trial will involve around 64 participants, including healthy volunteers and DMD patients, and results are expected in late 2023. Avidity emphasizes its ongoing commitment to deliver effective treatments for rare diseases, as AOC 1044 is one of several AOCs in development for DMD.
Avidity Biosciences, Inc. (NASDAQ: RNA) announced on April 20, 2023, that its Human Capital Management Committee granted stock options and restricted stock units (RSUs) to 12 new non-executive employees. Specifically, 58,300 stock options and 29,150 RSUs were awarded under the 2022 Employment Inducement Incentive Award Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $15.75, equal to the closing stock price on the grant date. The options will vest over four years, while the RSUs will vest in four equal installments over four years. Avidity focuses on developing a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), with ongoing clinical trials for several conditions, including myotonic dystrophy and Duchenne muscular dystrophy.
Avidity Biosciences, Inc. (Nasdaq: RNA) announced its upcoming presentations at the 75th American Academy of Neurology (AAN) Annual Meeting occurring in Boston from April 22-27, 2023. Key highlights include an oral presentation on April 27, focusing on the AOC 1001 Phase 1/2 MARINA™ trial, which evaluates the safety, biomarker, and functional data for patients with Myotonic Dystrophy Type 1 (DM1). Additionally, a poster presentation on April 23 will cover the AOC 1020 trial design for patients with Facioscapulohumeral Muscular Dystrophy (FSHD). Avidity's commitment is to advance its RNA therapeutics, specifically Antibody Oligonucleotide Conjugates (AOCs™), targeting diseases previously considered untreatable. For more information, visit Avidity's website.
Avidity Biosciences (Nasdaq: RNA) announced an investor and analyst event on April 27, 2023, in Boston, showcasing topline safety, biomarker, and functional data from the AOC 1001 Phase 1/2 MARINA trial for myotonic dystrophy type 1 (DM1). The event, starting at 5:30 p.m. ET, will be accessible via webcast. Lead investigator Nicholas E. Johnson will present this data earlier that day at the 75th American Academy of Neurology Annual Meeting. Avidity’s AOC 1001 aims to address DM1, part of a growing pipeline of innovative RNA therapeutics, which also includes treatments for facioscapulohumeral muscular dystrophy and Duchenne muscular dystrophy. The company continues to advance its mission to deliver targeted therapies to previously untreatable diseases.